

PRINTING CODE. Deletions appear in ~~this style type~~. Insertions appear in this style type. Typeface changes are shown in **this** *this* this style **type** or in **this** *this* this style **type**.

SENATE BILL No. 157

Proposed Changes to introduced printing by AM015701

DIGEST OF PROPOSED AMENDMENT

Disclosures related to prescription drugs. Requires a pharmacist or pharmacy to provide the amount of the national average drug acquisition cost for a generic drug on the written materials provided to an individual at the point of sale of the generic drug.

A BILL FOR AN ACT to amend the Indiana Code concerning insurance.

Be it enacted by the General Assembly of the State of Indiana:

1 ~~SECTION 1. IC 27-1-24.6-1, AS ADDED BY P.L.216-2025,~~
2 ~~SECTION 41, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE~~
3 ~~JULY 1, 2026]: See. 1. (a) This chapter applies to generic drugs~~
4 ~~covered under a health plan after December 31, 2025.~~
5 ~~(b) The amendments made to this chapter in the 2026 session~~
6 ~~of the general assembly apply to generic drugs covered under a~~
7 ~~health plan after December 31, 2026.~~
8 ~~SECTION 2. IC 27-1-24.6-1.5 IS ADDED TO THE INDIANA~~
9 ~~CODE AS A NEW SECTION TO READ AS FOLLOWS~~
10 ~~[EFFECTIVE JULY 1, 2026]: See. 1.5. As used in this chapter,~~
11 ~~"covered individual" means an individual who is entitled to~~
12 ~~coverage under a health plan.~~
13 > SECTION ~~2~~1. IC 27-1-24.6-6, AS ADDED BY P.L.216-2025,
14 ~~SECTION 41, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE~~
15 ~~JULY 1, 2026]: Sec. 6. (a) A health plan must provide the amount of~~
16 ~~the national average drug acquisition cost for a generic drug~~
17 ~~(1) to the plan sponsor~~and
18 ~~(2)~~l.
19 (b) A pharmacist (as defined in IC 27-1-24.5-9) or pharmacy

2026

IN 157—LS 6545/DI 154



DOCUMENT HAS NOT BEEN CHECKED FOR ACCURACY

1 (as defined in IC 27-1-24.5-11) must provide the amount of the
2 national average drug acquisition cost for a generic drug] on the
3 written materials provided to <the covered>[an] individual at the
4 point of sale of the generic drug.1
5 1

M

a

r

k

u

p

2026

IN 157—LS 6545/DI 154



DOCUMENT HAS NOT BEEN CHECKED FOR ACCURACY